雅戈爾(600177.SH):崑崙信託擬減持不超2%股份
格隆匯4月2日丨雅戈爾(600177.SH)公佈,截至2021年4月2日收盤,崑崙信託有限責任公司(以下簡稱“崑崙信託”)“崑崙信託·添盈投資一號集合資金信託計劃”賬户持有公司無限售流通股5.29億股,佔公司總股本的11.43%。
崑崙信託出於資金安排需要,擬通過集中競價等法律法規允許的方式減持“崑崙信託·添盈投資一號集合資金信託計劃”賬户所持有的部分無限售流通股,減持期間自公吿之日起十五個交易日後至2021年10月26日;計劃集中競價減持股份不超過9258.0059萬股,即不超過公司總股本的2%(若此期間公司有送股、資本公積金轉增股本、配股等除權事項,減持股份的數量將相應進行調整)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.